From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abcam PLC
Public company
Traded as LSEABC
Industry Biotech, Life sciences
Founded 1998
Key people
Alan Hirzel CEO
Products Research antibodies, kits and assays for biological research
Revenue Increase £97.8m (2012)[1]
Profit Increase £38.6m (2012)[1]
Number of employees
> 850 (2015)[1]

Abcam plc is a global biotech company based in the Cambridge Science Park in Cambridge, UK, with offices in Cambridge (Massachusetts, US), San Francisco, Hong Kong, Shanghai, and Tokyo.


The idea for the company originated in the University of Cambridge laboratory,[clarification needed] UK in 1998. The principal founder Jonathan Milner was a postdoctoral researcher studying the newly discovered breast cancer protein BRCA2 in Professor Tony Kouzarides' laboratory. The project slowed because of problems finding quality antibody reagents that had honest and up-to-date information about their uses and limitations. This scenario provided the motivation to form an on-line service that would help themselves and researchers across the globe.

Since its inception in 1998, the company has diversified from carrying only antibodies. It now supplies antibody-related products such as peptides and equipment.

Abcam is a life-science e-commerce company which facilitates public customer feedback on products using reviews and ratings which customers can submit. This has given rise to the nickname "the Amazon of antibodies"[2][3]

Abcam is also listed on the London Stock Exchange.


In May 2011, Abcam announced the acquisition of MitoSciences, a privately held biotech company based in Eugene, Oregon (US). The company produced and distributed immunoassay platforms and high performance monoclonal antibodies. It was founded in 2004 with the mission of advancing mitochondrial research and developing products that support critical research in cancer, neurodegeneration, and metabolic disorders.

On 12 September 2011, Abcam completed the purchase of Ascent Scientific. Ascent Scientific was a company based in Bristol, United Kingdom that provided high-quality biochemical products that modulate the function of proteins for use in life science research.[1]

On 19 April 2012, Abcam completed the purchase of Epitomics. Epitomics was a privately held biotech company in San Francisco that focused on the development, production, and distribution of rabbit monoclonal antibodies for biomedical research and diagnostic applications.[1]


  1. ^ a b c d e "Abcam 2012 Annual Report" (PDF). Abcam PLC. September 2012. Retrieved 19 November 2012. 
  2. ^ "Midas Extra share tips: Abcam & Vectura". This Is Money. 1 February 2009. Retrieved 9 March 2009. 
  3. ^ "Babraham to spin out antibody tyro". Business Weekly. 19 March 2008. Retrieved 9 March 2009. [dead link]

External links[edit]